the accuracy of tests of fetal health done in response to altered movements has been poorly evaluated, and the only treatment-delivery-can harm as well as benefit. 5 A 2015 Cochrane review 6 on routine perinatal fetal movement counting was dominated by a cluster trial by Adrian Grant and colleagues, 7 who investigated routine use of movement counting among 68 000 women and found that this method "did not translate into reduced perinatal mortality".
Nevertheless, encouraging maternal awareness of changes in fetal movements remains popular; this suggestion was advocated by the Saving Babies' Lives publication by NHS England, 8 largely on the basis of a study 9 that compared awareness campaigns with historical controls. This is weak evidence because other changes, such as increasing the frequency of term inductions and reduced smoking among pregnant mothers, could also have prevented stillbirth.
However, in The Lancet, Jane Norman and colleagues 10 have more thoroughly evaluated this policy. This stepped-wedge, cluster-randomised trial assessed a programme that encouraged enhanced maternal awareness and rapid reporting of changes in fetal movement, which was combined with training of staff to respond with a defined programme of further testing and, if necessary, to induce delivery. The advice to pregnant women was that they should monitor changes in movements from 24 weeks, and that they should refer themselves immediately if they detected altered movement after 28 weeks. Control centres gave usual care, and the primary outcome was stillbirth. More than 400 000 pregnancies at 33 hospitals were included, so the study was powered to exclude even modest effects. The intervention was associated with an induction rate of 41%, compared with 36% in the control group (adjusted odds ratio [AOR] 1·05, 95% CI 1·02-1·08); if the correct women had been induced and no harm caused, this intervention should have had a substantial effect. The Saving Babies' Lives stated that the AFFIRM trial "will give us the best evidence yet". 8 Unfortunately, stillbirths were not significantly reduced by this intervention (AOR 0·90, 95% CI 0·75-1·07) and there was no effect on perinatal mortality (0·98, 0·83-1·17). However, appendix data showed a higher number of postneonatal deaths in those receiving the intervention than in the control group. The intervention also had associated costs, including a significantly higher use of caesarean sections of 28%, compared with 25% in the control group (1·09, 1·06-1·12), and more prolonged admissions to the neonatal unit (1·12, 1·06-1·18).
The trial was prospectively registered and well conducted, and the results are plausible. Altered fetal movements are so commonly reported that the specificity of these reports must be low; some hospitals have more women attending for this reason than for births over the same period. Repeated episodes of reduced fetal movement can be so stressful to the mother that some doctors are persuaded to induce, even if further tests are normal. There are also anecdotes of women feigning reduced fetal movements to attain an ultrasound scan or induction of labour. The prevalence of women falsifying reduced fetal movement is important because, although induction of birth at full term is unlikely to seriously harm the mother or the baby, 11 preterm induction has risks. With hindsight, the recommendation to encourage mothers to report changes from as early as 28 weeks might have been misguided. Although overall deaths were not stratified by duration of gestation, it is plausible that limiting awareness campaigns to beyond 37 weeks would be safer. Two other cluster trials are ongoing: My Baby's Move ments among 250 000 women in Australia (Aus tralian New Zealand Clinical Trials Registry, ACTRN12614000291684) and Mindfetal among 39 000 women in Sweden (ClinicalTrials.gov, NCT02865759), so the AFFIRM authors suggest delaying policy changes until results of these trials are reported.
Nevertheless, given that the AFFIRM trial assesses a large population and is in agreement with the only previous large trial, 7 opinion and practice leaders need to consider how current guidelines might be revised. Failure of health-care providers to respond to reported changes to fetal movement is probably impossible. However, discouraging campaigns that promote awareness preterm, improving induction guidelines, and not inducing delivery in response to perception of altered movement alone would seem to be sensible first steps.
Kate F Walker, *Jim G Thornton
Division of Child Health, Obstetrics, and Gynaecology, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK jim.thornton@nottingham.ac.uk JGT reports personal fees and non-financial support from Ferring Pharmaceuticals, outside the area of work commented on here. KFW declares no competing interests.
